| Similar Articles |
|---|
 |
Pharmaceutical Executive
February 1, 2011
Jon Zifferblat |
China: Business as UNusual If there is one market that requires a click on the 'refresh' button, it's China. General Biologic provides a snapshot of what's ahead for Big Pharma in the country   |
Chemistry World
March 25, 2010
Rebecca Trager |
Big pharma scores in US healthcare reform President Obama has signed the biggest US healthcare reform since the 1960s, and although it is largely seen as a victory for the pharmaceutical industry, some analysts are characterising it as a 'double-edged sword'. |
Pharmaceutical Executive
December 1, 2012
Hager & Temme |
Germany's Price Reform Revolution At two years and counting, what's the secret of success in negotiating pricing under the new Act on Reform of the Market for Pharmaceutical Products legislation? |
Pharmaceutical Executive
October 1, 2012
J. Michael Nicholas |
Complex Drugs and Biologics: Policy Considerations in Brazil The Brazilian government's policy on biologics doesn't adequately address non-biologic complex drugs. Additional guidance is needed to bring these important medicines to market. |
Pharmaceutical Executive
November 1, 2008
Sarah Houlton |
Cash Flow Woes in EU In Europe, the wildly different attitudes toward healthcare across the different member states make for a complex pharmaceutical marketplace. |
Pharmaceutical Executive
August 1, 2011 |
Europe in HTA Gridlock Health technology assessments are gridlocked by diverse national requirements, a lack of alignment on processes, and even on the value of their outcomes. |
Pharmaceutical Executive
February 1, 2012 |
Brazil Report: A Bold Player Blooms Brazil was the last country to enter the fiscal crisis, but also the first to exit. And with a burgeoning middle class and a staunch commitment to national development, its pharmaceutical future is now. |
The Motley Fool
November 30, 2010
Brian Orelli |
A Witty Response to Pharma's R&D Dilemma According to GlaxoSmithKline CEO Andrew Witty, the pharmaceutical industry is a mess. That's the basic gist of his opinion piece in The Economist. |
Pharmaceutical Executive
June 1, 2011 |
Are You Ready for the New China? The ability to act as a good corporate citizen and assert a useful role in national industrial policy on health is going to be essential to success in the new China. |
Pharmaceutical Executive
February 1, 2009
Jill Wechsler |
Securing Savings A close look at the healthcare industry will separate real cost-cutting measures from money-saving myths. |
Chemistry World
November 21, 2008
Pete Mitchell |
UK drug price deal finalised The new deal is guaranteed to continue for five years - a great relief to the industry. |
Pharmaceutical Executive
November 1, 2013 |
Roundtable on Market Access Market Access is a window on what matters in the real world of soaring patient expectations and crimped payer budgets for innovation. |
Pharmaceutical Executive
January 21, 2014
Comer & Upton |
Pharm Exec's Annual Industry Outlook 2014 For Big Pharma, the merits of strategic focus and operational discipline are more important than ever. It is time to be decisive; muddling through is so yesterday. |
The Motley Fool
December 1, 2011
Neha Chamaria |
What's Drawing Equipment Makers to Brazil? Big companies are wisely making a beeline for the region. Equipment makers are making sure they do not miss out on the Brazilian growth story. |
Chemistry World
July 25, 2012 |
Pharma Industry May Suffer as India Looks to Generics India plans to provide free generic drugs to half its population. |
Pharmaceutical Executive
September 1, 2012
Stan Bernard |
The Payer C Change: From Customers to Competitors "Payers have evolved to become powerful global contenders with pharma for increasingly limited funding of drug budgets." Understanding why and how this payer shift to dominance occurred is critical for pharmaceutical professionals in adjusting their business model. |
Pharmaceutical Executive
November 1, 2014
Jill Wechsler |
Outrage Grows Over Drug Pricing Insurers, physicians attack high-cost therapies in anticipation of specialty drug surge. |
Chemistry World
October 11, 2007
Hepeng Jia |
China's Drug Industry Set to Take Off Producing cheap drugs for the developing world could allow Chinese pharmaceutical firms to capture a bigger share of the international market, industry experts suggest. |
Pharmaceutical Executive
October 1, 2010 |
Taking a Less-Generic Route to Generics A leading pharmaceutical industry player speaks out on what is fueling success in the sector. |
Pharmaceutical Executive
April 1, 2009
Jill Wechsler |
Kickoff for Reform In addition to overhauling healthcare, Congress is weighing proposals for updating FDA policies and expanding access to drugs. |
Pharmaceutical Executive
July 3, 2007
Humphrey Taylor |
Opinion: Lead, Follow, or Get Out of the Way A comparative-effectiveness board is coming. The pharmaceutical industry's wise will embrace the change. |
Pharmaceutical Executive
October 1, 2006
Ray Hill |
China: Big Rewards. Bigger Risks? The world's fastest growing pharmaceutical market may one day be the largest. Breaking in could be industry's greatest challenge. |
The Motley Fool
April 26, 2007
Brian Lawler |
Brazil's Boneheaded Drug Move Brazil already receives a steep discount on the price that Merck charges it for its HIV compounds. Nevertheless, it wants still lower prices to help reduce the government's costs associated with supplying drugs to those living with HIV/AIDS. |
The Motley Fool
January 31, 2007
Brian Lawler |
FDA Says Hurray for More Drug Safety The FDA outlines its proposal to increase drug safety. Whatever the FDA does, pharmaceutical investors should hope that its renewed interest in drug safety doesn't make the already lengthy process of bringing drugs to market any longer. |
Pharmaceutical Executive
July 3, 2007 |
Harbingers of Change What to watch, and watch out for, in the bottom half of '07. The IMS Health Editorial Board identifies what it believes are the key events that will impact the global pharmaceutical market in the near future. |
Pharmaceutical Executive
July 1, 2012
Jill Wechsler |
Who Will Pay for New Drugs? Comparative research documenting value and affordability is key to obtaining coverage for high-cost therapies. |
The Motley Fool
July 31, 2009
Brian Orelli |
Can Emerging Markets Save Pharma? Probably not until after they emerge. |
Pharmaceutical Executive
December 1, 2010 |
The Sum of All His Parts: Career Reflections of Europe's Chief Drug Regulator The European Medicines Agency is a unique institution, pursuing a mandate shared with a complex web of national and regional groups, each able to place a distinctive imprint around the delicate task of certifying the safety and efficacy of new drugs. |
IDB America
January 2003
Daniel Drosdoff |
Reaping the fruits of fiscal reform In exchange for financial discipline and transparency, Brazil's states and municipalities get more control over their budgets |
The Motley Fool
March 18, 2004
Brian Gorman |
The Drug Cost Conundrum While drug prices continue to climb, the public and its representatives in government are demanding cheaper pharmaceuticals. The industry is not likely to find cover in Medicare biotechnology. Instead, investors should look for drug makers that are finding ways to operate leaner and meaner. |
Searcher
June 2012
Stephanie C. Ardito |
The Medical Digital: How Safe Are the Prescription Drugs we Take? Monitoring Adverse Events and Recalls For general information about prescription and clinical trial drugs, the following websites have been around for a while and have excellent reputations. |
Chemistry World
March 27, 2013
Eugene Gerden |
Russian investment vehicle sets sights on innovative drugs Russian state-owned nanotechnology giant Rusnano is hoping to break into the pharmaceutical sector with sizeable investments in firms seeking to produce innovative drugs. |
IDB America
February 2002
Charo Quesada |
Leadership, consensus, and technology With broad support from society, Brazil is improving the quality of life of HIV carriers... |
Pharmaceutical Executive
August 1, 2011
Ben Comer |
Is the 'Emerging Market' a Dated Concept? When it comes to the emerging markets, executing a few key elements of success are more important than ever. |
The Motley Fool
November 19, 2007
Alex Dumortier |
Find the World's Best Caipirinha and a Huge Opportunity in Housing When in Brazil, you'll find a fast-growing, stable housing market, and maybe a really good Caipirinha. |
IndustryWeek
November 16, 2011
Steve Minter |
Brazil is Booming For U.S. manufacturers, the "country for the future" has arrived. |
